復旦張江(688505.SH):鹽酸氨酮戊酸顆粒劑用於膀胱癌手術可視化驗證性臨牀試驗完成首例受試者入組
格隆匯3月13日丨復旦張江(688505.SH)公佈,公司研發的鹽酸氨酮戊酸顆粒劑(以下簡稱“該藥物”)用於非肌層浸潤性膀胱癌手術切除輔助的驗證性臨牀研究於近日成功完成首例受試者入組。
本公司於2024年獲得該藥物研究的臨牀試驗批準通知書。該藥物研究旨在評價膀胱癌患者口服鹽酸氨酮戊酸顆粒劑用於熒光引導下腫瘤切除術的有效性和安全性。截至本公告披露日,該藥物研究已完成首例受試者入組。待本臨牀試驗完成後,根據相關法律法規,可提交該藥物的上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.